Emerging evidence implicates Serpin family A member 1 (SERPINA1/α1-antitrypsin), a serine protease inhibitor and acute-phase glycoprotein, as a multifaceted regulator of tumor progression and therapy resistance across malignancies such as pancreatic and lung cancer, primarily through inhibition of apoptosis and promotion of epithelial-mesenchymal transition [11, 12]. Here, SERPINA1 is linked to lung cancer.